CORRESP Filing
Shuttle Pharmaceuticals Holdings, Inc.
Date: Feb. 13, 2026 · CIK: 0001757499 · Accession: 0001493152-26-006667
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293363
Letter
Shuttle Pharmaceuticals Holdings, Inc.
Professional Drive, Suite 260
Gaithersburg, MD 20879
February 13, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499)
Registration Statement No. 333-293363 on Form S-1 (the "Registration Statement")
Ladies and Gentlemen:
Shuttle Pharmaceuticals Holdings, Inc. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on February 17, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Aaron Schleicher, Esq. of Sullivan & Worcester LLP at (212) 660-3034 and that such effectiveness also be confirmed in writing.
Very
truly yours,
Shuttle
Pharmaceuticals Holdings, Inc.
Show Raw Text
CORRESP 1 filename1.htm Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 February 13, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499) Registration Statement No. 333-293363 on Form S-1 (the "Registration Statement") Ladies and Gentlemen: Shuttle Pharmaceuticals Holdings, Inc. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on February 17, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable. The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Aaron Schleicher, Esq. of Sullivan & Worcester LLP at (212) 660-3034 and that such effectiveness also be confirmed in writing. Very truly yours, Shuttle Pharmaceuticals Holdings, Inc. By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer